A Randomized, Double-Blind, Phase 2 Trial of Fulvestrant Plus Enzastaurin versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer
- Registry ID
- EUCTR2006-005305-58
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Eli Lilly and Company limited
- Start date
- 2007-02-02
- Completion date
- 2018-10-18
- Last update
- 2026-08-16
Conditions
- Aromatase Inhibitor-Resistant Metastatic Breast Cancer
- locally advanced or metastatic breast cancer
- metastatic breast cancer, resistant to aromatase inhibitors
Summary
Main objective : To compare the clinical benefit rate between fulvestrant plus enzastaurin and fulvestrant plus placebo in Aromatase Inhibitor resistant MBC.
Locations
- , , Germany
- , , France
- , , Netherlands
- , , Spain
- , , Italy
View on source registry